ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway.
about
Mutant p53 and ETS2, a Tale of ReciprocityDissecting Alzheimer disease in Down syndrome using mouse modelsAdvanced microscopic imaging methods to investigate cortical development and the etiology of mental retardation.Genetic dissection of the Down syndrome critical region.Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation.The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism.Increased survival following tumorigenesis in Ts65Dn mice that model Down syndrome.Disruption of neurogenesis and cortical development in transgenic mice misexpressing Olig2, a gene in the Down syndrome critical regionTrisomic and allelic differences influence phenotypic variability during development of Down syndrome mice.The use of mouse models for understanding the biology of down syndrome and agingDeregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary TumorsMiR-1246: a new link of the p53 family with cancer and Down syndrome.Ets1 as a marker of malignant potential in gastric carcinoma.Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-tagged RCAN1 (DSCR1)Non-conventional apoptotic response to ionising radiation mediated by N-methyl D-aspartate receptors in immature neuronal cells.Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndromeTrisomy 21 and Down syndrome: a short review.Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.Unique clinical and biological features of leukemia in Down syndrome children.Is it possible to improve neurodevelopmental abnormalities in Down syndrome?Preparation, crystallization and preliminary X-ray diffraction analysis of the DNA-binding domain of the Ets transcription factor in complex with target DNA.Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice.DUSP6 is a novel transcriptional target of p53 and regulates p53-mediated apoptosis by modulating expression levels of Bcl-2 family proteins.Synthetic combinations of missense polymorphic genetic changes underlying Down syndrome susceptibility.HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.Th2 responses are primed by skin dendritic cells with distinct transcriptional profiles.P53 Dysfunction in Neurodegenerative Diseases - The Cause or Effect of Pathological Changes?Role for Ets-2(Thr-72) transcription factor in stage-specific thymocyte development and survivalEndothelial cells' activation and apoptosis induced by a subset of antibodies against human cytomegalovirus: relevance to the pathogenesis of atherosclerosisApoptosis in Down's syndrome: lessons from studies of human and mouse models.Transcription Factor Ets-2 Acts as a Preinduction Repressor of Interleukin-2 (IL-2) Transcription in Naive T Helper Lymphocytes.Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology.Complex contributions of Ets2 to craniofacial and thymus phenotypes of trisomic "Down syndrome" mice.Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.Mitochondrial dysfunction in down syndrome: molecular mechanisms and therapeutic targets.
P2860
Q26765746-C3149A78-02D6-4FEE-962C-B9B3FFFED901Q26777254-124F0238-89B4-4684-B8AC-6571F134C044Q30487112-2E5217B1-D7B5-4F82-8E94-314990FFBF30Q30670043-3F05AECC-F4AB-4408-807A-5D78A090640EQ33840456-2AF30194-D2D7-4E42-8282-EF7F6655D5F1Q34347627-FE560C84-E397-4774-8F53-BBA568D6145AQ34988075-9D99D45F-87A9-4A76-B18C-CBD21A9080ACQ35596333-D2C5F741-6EDB-41D3-9F36-4BC1533A5F6BQ35620481-2D35994D-8A3B-4A98-93F6-A4421787DCD7Q35810481-7B5CD2DA-341A-4BFD-B0BF-EE20AC3323BCQ35932525-AECE30E4-63A1-4024-AFE4-08C1CCB2E820Q36130066-CB62CDA5-3F79-45B3-AFA5-964673AD296CQ36308623-A1C6008F-AF35-4446-A33F-BFF7CA4204D5Q36344071-1278E952-FFC8-4A09-BC95-B297065FC293Q36581939-DE1531AA-32D5-4BFD-916B-D81F8D3C6500Q36684562-3FE25E11-D09F-45FB-9BBC-872F89ED3B49Q37095280-216178E7-CAF8-492A-B6AB-ECC21F40D7C0Q37142140-5B236B70-1010-4BBC-AE8A-3B0B1FF6D50AQ37228422-BD87159F-71F6-47BB-9372-89C8F36DCBB9Q37662773-41134BBF-2B06-4A04-A08C-2137AEE2F562Q37810271-0BD1FF2F-A17D-4286-B2E6-41F3772FACA8Q37912174-E33604F6-49F6-4F38-A711-34FBC073C3CAQ38272782-8767FF84-882F-4076-8001-645A8A0AAE2FQ38287490-F64F64EF-163C-4863-B46D-2C0279ADC975Q38457010-BCF5EFCC-336E-41D4-AAB7-07325027C475Q38849213-3D771ED9-19F8-4694-9EC1-A71335543C6CQ39006663-55874BFF-54B5-49DB-B9B3-7E0F8B8FC843Q40540246-FCA3B1BA-5168-4A01-AC24-1D87FEC848EAQ41108776-3AD15AC3-656E-4D08-88B5-81348EEC45FDQ41479119-54342151-C265-4699-9ECB-9BDBB3E544F3Q42791617-33AC1928-9E59-45C8-AFBE-546CB3F6E5A8Q43723779-2D87174B-7026-4B65-A606-A9E129E9B077Q50614253-8938421C-B7C8-4754-B946-0306D135DD8BQ50732745-A23FDB51-243F-4499-A8BA-203DC8A28191Q51926009-66865354-3575-40E7-A5D0-1355BE8520D9Q53177105-1147A1FF-3BAB-4786-A36B-3C298C4FD406Q55502644-123641AF-A24B-454C-B90A-414FC9475D71
P2860
ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
ETS2 overexpression in transge ...... apoptosis via the p53 pathway.
@en
type
label
ETS2 overexpression in transge ...... apoptosis via the p53 pathway.
@en
prefLabel
ETS2 overexpression in transge ...... apoptosis via the p53 pathway.
@en
P2093
P356
P1476
ETS2 overexpression in transge ...... apoptosis via the p53 pathway.
@en
P2093
Busciglio J
Hatzistavrou T
Hertzog PJ
P304
P356
10.1093/HMG/DDG015
P577
2003-02-01T00:00:00Z